ANI Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ANIP ANI Pharmaceuticals Inc
CHUY Chuy's Holdings Inc
HBUV Hubilu Venture Corporation
LMNL Liminal BioSciences Inc
NXTD NXT-ID Inc
RIOT Riot Blockchain Inc
HIHO Highway Holdings Ltd
CBAY Cymabay Therapeutics Inc
DTSS Datasea Inc
MOXC Moxian Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Closing Price
$29.86
Day's Change
0.25 (0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
29.86
Day's Low
28.42
Volume
(Average)
Volume:
88,887

10-day average volume:
96,367
88,887

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, August 03, 2020
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that Nikhil Lalwani has been named the Company's President and Chief Executive Officer, effective September 8, 2020. Mr. Lalwani will also be elected to the Company's...(BusinessWire)

July 30, 2020
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial Results

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, before the opening of the U.S. financial markets. (BusinessWire)

July 10, 2020
Cancer Cachexia Market to Reach USD 2.93 Billion by 2027; Rapid Inclination towards Combination Therapies to Aid Growth: Fortune Business Insights(TM)

The global cancer cachexia market is anticipated to gain traction from the rising shift of the healthcare providers towards combination therapies. Such therapies are aiding in improving the lean body mass (LBM) of patients. This information is...(Globe Newswire)

July 06, 2020
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million. The current annual U.S. market for this product is approximately $40...(PR Newswire)

June 30, 2020
ANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride Capsules

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg. The current annual U.S. market for this product is approximately $16 million, according to IQVIA/IMS Health. (PR Newswire)

June 01, 2020
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the FDA relating to its Cortrophin(R) Gel sNDA filing. (PR Newswire)

May 07, 2020
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

For the first quarter 2020, ANI reports: -- Net revenues of $49.8 million versus $52.9 million in 2019 -- GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 -- Adjusted non-GAAP EBITDA of $17.6 million (PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.